ODT Staff03.04.22
Hyprevention Inc.'s U.S. subsidiary is edging closer to its debut.
The French company has raised $4.5 million for establishing an American division and rolling out its STRUTPLASTY platform in the country. Hyprevention's STRUTPLASTY platform aims to reinforce bone in case of fractures or impending fractures. The technology is protected by 25 patents, including in the United States of America and Europe. Two products are currently on the market and the platform will be expanded to address more anatomical sites.
”There are over 60 million people suffer from vertebral compression fractures in Asia. Due to lack of effective and affordable medical devices on the market, the doctors still apply the tradition vertebroplasty treatments on patients," said Chan-Yuan (Branford) Lu from Yellowstone Holding. "We believe VSTRUT device has huge market potential in the near future.”
In 2020, Hyprevention's V-STRUT Vertebral Implant obtained U.S. Food and Drug Administration 510(k) clearance and the company formed its U.S. subsidiary last year in order to launch the device in America. CEO Cécile Vienney moved to New York City to develop and manage the subsidiary, closer to the product's users. The first clinical cases are very promising. Post-market clinical studies will be conducted to continuously show the high performance of the products to address real clinical needs.
Hyprevention raised the funds with Yellowstone Holding and existing shareholders.
“STRUTPLASTY technology is unique on the market. Hyprevention develops easy-to-use products with a high clinical benefit thanks to a good understanding of biomechanics and users’ needs. We are very happy by the high interest we get from U.S. practitioners and are glad to build a success story,” said Vienney.
Yellowstone Holding AG is a Geneva based medtech investment company.
Founded in 2010 by Vienney and three orthopedic surgeons, Hyprevention is a startup located in Bordeaux-France that develops, manufactures, and markets implantable medical devices.
The French company has raised $4.5 million for establishing an American division and rolling out its STRUTPLASTY platform in the country. Hyprevention's STRUTPLASTY platform aims to reinforce bone in case of fractures or impending fractures. The technology is protected by 25 patents, including in the United States of America and Europe. Two products are currently on the market and the platform will be expanded to address more anatomical sites.
”There are over 60 million people suffer from vertebral compression fractures in Asia. Due to lack of effective and affordable medical devices on the market, the doctors still apply the tradition vertebroplasty treatments on patients," said Chan-Yuan (Branford) Lu from Yellowstone Holding. "We believe VSTRUT device has huge market potential in the near future.”
In 2020, Hyprevention's V-STRUT Vertebral Implant obtained U.S. Food and Drug Administration 510(k) clearance and the company formed its U.S. subsidiary last year in order to launch the device in America. CEO Cécile Vienney moved to New York City to develop and manage the subsidiary, closer to the product's users. The first clinical cases are very promising. Post-market clinical studies will be conducted to continuously show the high performance of the products to address real clinical needs.
Hyprevention raised the funds with Yellowstone Holding and existing shareholders.
“STRUTPLASTY technology is unique on the market. Hyprevention develops easy-to-use products with a high clinical benefit thanks to a good understanding of biomechanics and users’ needs. We are very happy by the high interest we get from U.S. practitioners and are glad to build a success story,” said Vienney.
Yellowstone Holding AG is a Geneva based medtech investment company.
Founded in 2010 by Vienney and three orthopedic surgeons, Hyprevention is a startup located in Bordeaux-France that develops, manufactures, and markets implantable medical devices.